Eli Lilly and Company, Johnson & Johnson, and Regeneron Pharmaceuticals are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell medicines and related treatments. For investors, their performance can be influenced by drug sales, clinical-trial results, regulatory approvals, patent expirations, and healthcare policies. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded up $16.77 during midday trading on Friday, reaching $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,460.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The firm has a 50 day simple moving average of $1,242.25 and a 200-day simple moving average of $1,110.30. The stock has a market cap of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of JNJ stock traded up $2.26 on Friday, hitting $285.78. 6,279,519 shares of the stock traded hands, compared to its average volume of 7,472,752. The firm's 50-day moving average price is $266.97 and its two-hundred day moving average price is $249.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a market capitalization of $687.95 billion, a PE ratio of 43.30, a PEG ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11.
Read Our Latest Research Report on JNJ
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Shares of REGN traded up $4.28 during mid-day trading on Friday, reaching $955.47. The stock had a trading volume of 1,165,612 shares, compared to its average volume of 984,019. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $991.73. The firm has a market cap of $98.84 billion, a price-to-earnings ratio of 21.10, a P/E/G ratio of 1.26 and a beta of 0.10. The business's fifty day moving average is $816.17 and its 200 day moving average is $747.36. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89.
Read Our Latest Research Report on REGN
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
